Sales share at risk of pharmaceuticals due to patent expiries U.S. 2022
As of 2022, around 42 percent of all Humira U.S. sales are expected to be at risk due to the drug patent expiring in 2023. This statistic illustrates the share of sales at risk of pharmaceutical products in the U.S. due to approaching drug patent expiries.